###begin article-title 0
A homeostatic model of IkappaB metabolism to control constitutive NF-kappaB activity
###end article-title 0
###begin p 1
Present address: Department of Molecular Biology and Biochemistry, UCI, Irvine, CA 92697, USA
###end p 1
###begin p 2
Present address: 647 Lincoln Way, San Francisco, CA 94122, USA
###end p 2
###begin p 3
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits distribution, and reproduction in any medium, provided the original author and source are credited. This license does not permit commercial exploitation or the creation of derivative works without specific permission.
###end p 3
###begin p 4
###xml 670 677 650 657 <italic>in vivo</italic>
Cellular signal transduction pathways are usually studied following administration of an external stimulus. However, disease-associated aberrant activity of the pathway is often due to misregulation of the equilibrium state. The transcription factor NF-kappaB is typically described as being held inactive in the cytoplasm by binding its inhibitor, IkappaB, until an external stimulus triggers IkappaB degradation through an IkappaB kinase-dependent degradation pathway. Combining genetic, biochemical, and computational tools, we investigate steady-state regulation of the NF-kappaB signaling module and its impact on stimulus responsiveness. We present newly measured in vivo degradation rate constants for NF-kappaB-bound and -unbound IkappaB proteins that are critical for accurate computational predictions of steady-state IkappaB protein levels and basal NF-kappaB activity. Simulations reveal a homeostatic NF-kappaB signaling module in which differential degradation rates of free and bound pools of IkappaB represent a novel cross-regulation mechanism that imparts functional robustness to the signaling module.
###end p 4
###begin title 5
Introduction
###end title 5
###begin p 6
###xml 305 332 305 332 <xref ref-type="bibr" rid="b3">Brivanlou and Darnell, 2002</xref>
Cellular signal transduction pathways mediate responses to extracellular and intracellular signals, such as changing environmental and metabolic conditions, pathogen assault, and developmental cues. Many signaling pathways control the activity of transcription factors that regulate cognate target genes (Brivanlou and Darnell, 2002). For immediate early transcriptional responses (not requiring induced synthesis), such regulation may involve the reversible phosphorylation of the transcription factor to induce dimerization or nuclear translocation (e.g. the Stat, IRF, AP-1 transcription factor families). An alternate means of pathway activation involves stabilization of the transcriptional effector, as in the case of the genotoxic response regulator p53, the hypoxia response factor HIF-1alpha, or the developmentally regulated coactivator beta-catenin. Thus, signaling in response to stimulus involves alterations of the homeostatic rates of synthesis and degradation found in unstimulated cells.
###end p 6
###begin p 7
###xml 313 322 305 314 <xref ref-type="fig" rid="f1">Figure 1A</xref>
###xml 325 353 317 345 <xref ref-type="bibr" rid="b5">Hoffmann and Baltimore, 2006</xref>
###xml 605 616 589 600 <xref ref-type="bibr" rid="b9">Karin, 2006</xref>
In contrast, the cellular abundance of the transcription factor NF-kappaB does not change dramatically during signaling. NF-kappaB is the critical mediator of cellular responses to a large number of physiological stimuli, including inflammatory cytokines, developmental signals, pathogens, and cellular stresses (Figure 1A) (Hoffmann and Baltimore, 2006). Although inflammatory signaling leads to transient NF-kappaB activity that is dynamically regulated by feedback mechanisms, elevated constitutive levels of active NF-kappaB are associated with chronic inflammatory diseases and many types of cancer (Karin, 2006).
###end p 7
###begin p 8
###xml 329 334 292 297 <italic>et al</italic>
###xml 323 340 286 303 <xref ref-type="bibr" rid="b4">Ghosh <italic>et al</italic>, 1998</xref>
###xml 556 561 493 498 <italic>et al</italic>
###xml 550 567 487 504 <xref ref-type="bibr" rid="b18">Scott <italic>et al</italic>, 1993</xref>
###xml 576 581 513 518 <italic>et al</italic>
###xml 569 587 506 524 <xref ref-type="bibr" rid="b11">Kearns <italic>et al</italic>, 2006</xref>
###xml 855 860 776 781 <italic>et al</italic>
###xml 849 866 770 787 <xref ref-type="bibr" rid="b4">Ghosh <italic>et al</italic>, 1998</xref>
###xml 874 879 795 800 <italic>et al</italic>
###xml 868 885 789 806 <xref ref-type="bibr" rid="b20">Yaron <italic>et al</italic>, 1998</xref>
NF-kappaB activity is inhibited by association with the inhibitor proteins, IkappaBalpha, IkappaBbeta, or IkappaBepsilon, which mask its nuclear localization sequence and inhibit its DNA-binding activity. The regulated metabolism of IkappaB proteins-their synthesis and degradation-critically controls NF-kappaB signaling (Ghosh et al, 1998). Synthesis of IkappaB proteins is a highly regulated process, with at least two isoforms, IkappaBalpha and IkappaBepsilon, being subject to NF-kappaB-inducible synthesis, thereby providing negative feedback (Scott et al, 1993; Kearns et al, 2006). Stimulus-induced IkappaB degradation is controlled by the IkappaB kinase (IKK), which phosphorylates two N-terminal serines. This leads to IkappaB polyubiquitination and degradation via the 26S proteasome, thus liberating NF-kappaB for nuclear translocation (Ghosh et al, 1998; Yaron et al, 1998).
###end p 8
###begin p 9
###xml 179 184 167 172 <italic>et al</italic>
###xml 170 190 158 178 <xref ref-type="bibr" rid="b6">Hoffmann <italic>et al</italic>, 2002</xref>
###xml 652 657 607 612 <italic>et al</italic>
###xml 642 663 597 618 <xref ref-type="bibr" rid="b13">Lipniacki <italic>et al</italic>, 2004</xref>
###xml 871 891 810 830 <xref ref-type="bibr" rid="b16">Rice and Ernst, 1993</xref>
###xml 871 875 <span type="species:ncbi:4530">Rice</span>
These processes were described in a mathematical model of the IKK-IkappaB-NF-kappaB signaling module to recapitulate NF-kappaB activation in response to TNF stimulation (Hoffmann et al, 2002). Its construction relied on rate constants available in the literature from a diverse set of experiments. As no isoform-specific data were available, rate constants pertaining to IkappaBbeta and IkappaBepsilon were assumed to be the same as those measured for IkappaBalpha. Although this model accurately recapitulates NF-kappaB signaling in response to TNF, in the unstimulated state the estimated IkappaB levels were found to be unexpectedly high (Lipniacki et al, 2004). In fact, the vast majority of IkappaB were calculated to be in the free form, contradictory to experimental studies showing that free IkappaBalpha accounts for less than 15% of the total cellular IkappaB (Rice and Ernst, 1993).
###end p 9
###begin p 10
###xml 389 394 373 378 <italic>et al</italic>
###xml 379 400 363 384 <xref ref-type="bibr" rid="b12">Krappmann <italic>et al</italic>, 1996</xref>
###xml 483 504 467 488 <xref ref-type="bibr" rid="b15">Pando and Verma, 2000</xref>
Despite our detailed understanding of stimulus-induced NF-kappaB signaling, there is less clarity about the mechanisms mediating IkappaB turnover in the absence of external stimulation. Early studies reported that basal turnover of IkappaB, unlike its induced degradation, does not require the IKK-targeted serines, the C-terminal PEST domain, or poly-ubiquitination of IkappaB (Krappmann et al, 1996), whereas others found robust C-terminal phosphorylation and poly-ubiquitination (Pando and Verma, 2000).
###end p 10
###begin p 11
###xml 215 236 195 216 <xref ref-type="bibr" rid="b15">Pando and Verma, 2000</xref>
###xml 327 332 295 300 <italic>et al</italic>
###xml 321 338 289 306 <xref ref-type="bibr" rid="b21">Zandi <italic>et al</italic>, 1998</xref>
###xml 410 419 378 387 <italic>in vitro.</italic>
###xml 566 571 530 535 <italic>et al</italic>
###xml 558 577 522 541 <xref ref-type="bibr" rid="b17">Schwarz <italic>et al</italic>, 1996</xref>
###xml 584 589 548 553 <italic>et al</italic>
###xml 579 595 543 559 <xref ref-type="bibr" rid="b2">Bren <italic>et al</italic>, 2000</xref>
###xml 698 703 654 659 <italic>et al</italic>
###xml 693 709 649 665 <xref ref-type="bibr" rid="b10">Kato <italic>et al</italic>, 2003</xref>
###xml 763 768 719 724 <italic>et al</italic>
###xml 753 774 709 730 <xref ref-type="bibr" rid="b12">Krappmann <italic>et al</italic>, 1996</xref>
###xml 776 810 732 766 <xref ref-type="bibr" rid="b1">Alvarez-Castelao and Castano, 2005</xref>
By distinguishing between NF-kappaB-bound and free IkappaB pools using an IkappaB interaction mutant, the half-life of bound IkappaB was found to be five-fold longer than that of free IkappaB in unstimulated cells (Pando and Verma, 2000). However, free IkappaB is a poorer substrate for IKK than NF-kappaB-bound IkappaB (Zandi et al, 1998), although it is routinely used as a substrate to measure IKK activity in vitro. Free IkappaB turnover was proposed to involve casein kinase 2 (CK2)-mediated phosphorylation of the C-terminal domain and ubiquitination (Schwarz et al, 1996; Bren et al, 2000), but others suggested that CK2 is involved in inducible degradation of NF-kappaB-bound IkappaB (Kato et al, 2003), or that ubiquitination was not required (Krappmann et al, 1996; Alvarez-Castelao and Castano, 2005).
###end p 11
###begin p 12
###xml 244 249 <span type="species:ncbi:10090">mouse</span>
Given these contradictory results in the literature, the lack of data on two of the three IkappaB isoforms, and the poor fit of computational simulations of the NF-kappaB signaling module in cells not exposed to TNF, we generated genetic tools-mouse knockout cell lines-to isolate cleanly the endogenous-free and -bound IkappaB protein pools and probe their degradation with kinase knockouts and pharmacological inhibitors. In addition, we used computational modeling (i) to identify which constitutive degradation rate constants play a critical role in determining stimulus responsiveness, (ii) to determine new biochemical rate constants based on our experimental results, (iii) to confirm the validity of the new parameters by simulating the cellular steady state, and (iv) to reveal the control of IkappaB degradation by NF-kappaB as a cross-regulatory mechanism.
###end p 12
###begin title 13
Results and discussion
###end title 13
###begin title 14
IKK-dependent and -independent degradation of IkappaBs determine NF-kappaB signaling
###end title 14
###begin p 15
###xml 43 50 43 50 <italic>in vivo</italic>
###xml 82 91 78 87 <xref ref-type="fig" rid="f1">Figure 1B</xref>
###xml 560 565 536 541 <italic>et al</italic>
###xml 551 571 527 547 <xref ref-type="bibr" rid="b6">Hoffmann <italic>et al</italic>, 2002</xref>
Four degradation rate constants govern the in vivo half-life of IkappaB proteins (Figure 1B). An IkappaB molecule can exist in either the free or NF-kappaB-bound form. Both forms may be degraded in an IKK-dependent manner (we denote the IkappaBalpha rate constants of these processes r1 and r4, respectively), but are also subject to constitutive degradation in an IKK-independent manner (with the rate constants denoted as deg1 and deg4). These mechanisms are described as first-order rate constants in our mathematical model of NF-kappaB signaling (Hoffmann et al, 2002).
###end p 15
###begin p 16
###xml 567 576 538 547 <xref ref-type="fig" rid="f1">Figure 1C</xref>
To explore the functional significance of each IkappaB degradation rate constant in NF-kappaB signal transduction, we performed simulations of TNF signaling after altering one of the four rate constants (simultaneously for the IkappaBalpha, beta, and epsilon isoforms) with a parameter multiplier ranging from 0.01 to 100. For each parameter multiplier, we calculated the average nuclear NF-kappaB level in response to TNF during the early phase (during the first hour of stimulation) and the later attenuation phase (during the second hour after a 4 h stimulation) (Figure 1C). By plotting the calculated NF-kappaB activity against its parameter multiplier, we can interpret the sensitivity of the system to each rate constant for two critical features of the NF-kappaB response to a transient TNF stimulus: activation and attenuation of NF-kappaB activity.
###end p 16
###begin p 17
###xml 316 325 300 309 <xref ref-type="fig" rid="f1">Figure 1D</xref>
###xml 457 466 429 438 <xref ref-type="fig" rid="f1">Figure 1D</xref>
###xml 659 668 623 632 <xref ref-type="fig" rid="f1">Figure 1E</xref>
###xml 780 789 740 749 <xref ref-type="fig" rid="f1">Figure 1E</xref>
We first examined the impact of changes in IKK-dependent IkappaB degradation rate constants on NF-kappaB activation. During the first hour of TNF stimulation, the amount of nuclear NF-kappaB calculated by the model is fairly insensitive to even drastic changes in the IKK-dependent degradation rate of free IkappaB (Figure 1D, blue line). In contrast, slowing down the IKK-induced degradation of NF-kappaB-bound IkappaB severely dampens NF-kappaB activity (Figure 1D, red line). During the attenuation phase, the amount of nuclear NF-kappaB predicted by the model was similarly found to be insensitive to changes in IKK-dependent degradation of free IkappaB (Figure 1E, blue line), but slowing the IKK-dependent degradation rate of bound IkappaB results in a loss of attenuation (Figure 1E, red line).
###end p 17
###begin p 18
###xml 462 471 446 455 <xref ref-type="fig" rid="f1">Figure 1F</xref>
###xml 507 516 487 496 <xref ref-type="fig" rid="f1">Figure 1F</xref>
###xml 703 712 675 684 <xref ref-type="fig" rid="f1">Figure 1G</xref>
The IKK-independent IkappaB degradation rates control the stimulus-independent turnover of IkappaB proteins, and thus maintain a resting state equilibrium of IkappaB levels. Examining whether these IKK-independent degradation rates play a role in determining the cellular responsiveness to inflammatory stimuli revealed that during the first hour of TNF stimulation the signaling module is dramatically more sensitive to the basal turnover rate of free IkappaB (Figure 1F, blue line) than of bound IkappaB (Figure 1F, red line). Furthermore, our simulations predicted that a more stable free IkappaB results in a loss of attenuation, whereas the basal turnover rate of the bound IkappaBs had no effect (Figure 1G).
###end p 18
###begin p 19
In sum, our computational simulations revealed that two of the four possible degradation pathways play a particularly important role in controlling NF-kappaB signaling. Whereas much is known about the stimulus-responsive IKK-mediated degradation pathway, the IKK-independent degradation mechanism of free IkappaB has received surprisingly little experimental attention. Given the importance of these degradation rate constants in our computational analysis, we set out to examine them in more detail experimentally.
###end p 19
###begin title 20
NF-kappaB regulation of IkappaB protein turnover and synthesis
###end title 20
###begin p 21
###xml 26 33 26 33 <italic>in vivo</italic>
###xml 208 232 196 220 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure S1A</xref>
###xml 513 522 489 498 <xref ref-type="fig" rid="f2">Figure 2A</xref>
###xml 524 548 500 524 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure S1B</xref>
###xml 1064 1069 974 979 <italic>et al</italic>
###xml 1055 1075 965 985 <xref ref-type="bibr" rid="b6">Hoffmann <italic>et al</italic>, 2002</xref>
###xml 1228 1237 1123 1132 <xref ref-type="fig" rid="f2">Figure 2B</xref>
###xml 1242 1266 1137 1161 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure S1C</xref>
To measure experimentally in vivo degradation rate constants for NF-kappaB-bound IkappaB proteins, we used the ribosomal inhibitor cycloheximide (CHX) to reduce the synthesis of new IkappaB proteins (by 85%; Supplementary Figure S1A), and examined the amount of nuclear NF-kappaB DNA-binding activity via electrophoretic mobility shift assay (EMSA). Treatment of wild-type MEFs with CHX over a 60 h time course induced nuclear NF-kappaB activity that corresponds to 25-35% of peak TNF-induced NF-kappaB activity (Figure 2A, Supplementary Figure S1B). To determine the relative contributions of each NF-kappaB-bound IkappaB isoform (alpha, beta, and epsilon) to CHX-mediated NF-kappaB activation, we used a panel of IkappaB double-knockout MEFs, which contain only one IkappaB isoform. These cells were previously used to determine the degradation rate constants for each IkappaB isoform by TNF-induced NF-kappaB activation, which revealed that upon IKK activation, IkappaBalpha was degraded most rapidly, followed by IkappaBepsilon, and then IkappaBbeta (Hoffmann et al, 2002). Interestingly, we find the same trend in stimulus-independent degradation, where IkappaBbeta is the most stable and IkappaBalpha is the least stable (Figure 2B and Supplementary Figure S1C).
###end p 21
###begin p 22
###xml 104 108 100 104 <italic>crel</italic>
###xml 108 111 104 107 <italic>&#8722;/&#8722;</italic>
###xml 108 111 104 107 <sup><italic>&#8722;/&#8722;</italic></sup>
###xml 111 115 107 111 <italic>rela</italic>
###xml 115 118 111 114 <italic>&#8722;/&#8722;</italic>
###xml 115 118 111 114 <sup><italic>&#8722;/&#8722;</italic></sup>
###xml 118 123 114 119 <italic>nfkb1</italic>
###xml 123 126 119 122 <italic>&#8722;/&#8722;</italic>
###xml 123 126 119 122 <sup><italic>&#8722;/&#8722;</italic></sup>
###xml 136 140 132 136 <italic>nfkb</italic>
###xml 140 143 136 139 <italic>&#8722;/&#8722;</italic>
###xml 140 143 136 139 <sup><italic>&#8722;/&#8722;</italic></sup>
###xml 397 406 381 390 <xref ref-type="fig" rid="f2">Figure 2C</xref>
###xml 484 487 468 471 <italic>ikb</italic>
###xml 492 495 472 475 <sup>&#8722;/&#8722;</sup>
###xml 499 502 476 479 <sup>&#8722;/&#8722;</sup>
###xml 509 512 480 483 <sup>&#8722;/&#8722;</sup>
###xml 567 571 530 534 <italic>nfkb</italic>
###xml 571 574 534 537 <italic>&#8722;/&#8722;</italic>
###xml 571 574 534 537 <sup><italic>&#8722;/&#8722;</italic></sup>
###xml 723 747 669 693 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure S2A</xref>
###xml 846 855 784 789 <italic>nf&#954;b2</italic>
To investigate the stability of the unbound, or 'free', IkappaB proteins in resting cells, we generated crel-/-rela-/-nfkb1-/- (termed 'nfkb-/-') MEFs deficient in the three NF-kappaB proteins known to interact with the classical IkappaB proteins: RelA, c-Rel, and p50. Western blots revealed a dramatic reduction in the amount of total IkappaB protein level in these cells compared to wild type (Figure 2C, compare lanes 3 and 6). A dilution series of wild-type protein extract with ikbalpha-/-beta-/-epsilon-/- extract showed that the amount of IkappaBalpha in the nfkb-/- cells was approximately one-twentieth the amount in wild-type cells, and that this ratio is probably even lower for IkappaBbeta and IkappaBepsilon (Supplementary Figure S2A). No decrease in IkappaB levels was detected in MEFs deficient in the NF-kappaB proteins RelB and nfkappab2 p52, which are non-canonical NF-kappaB proteins that do not bind canonical IkappaB proteins.
###end p 22
###begin p 23
###xml 50 54 42 46 <italic>nfkb</italic>
###xml 54 57 46 49 <italic>&#8722;/&#8722;</italic>
###xml 54 57 46 49 <sup><italic>&#8722;/&#8722;</italic></sup>
###xml 184 208 159 183 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure S2B</xref>
###xml 324 328 295 299 <italic>nfkb</italic>
###xml 328 331 299 302 <italic>&#8722;/&#8722;</italic>
###xml 328 331 299 302 <sup><italic>&#8722;/&#8722;</italic></sup>
###xml 356 360 327 331 <italic>nfkb</italic>
###xml 360 363 331 334 <italic>&#8722;/&#8722;</italic>
###xml 360 363 331 334 <sup><italic>&#8722;/&#8722;</italic></sup>
###xml 493 502 456 465 <xref ref-type="fig" rid="f2">Figure 2C</xref>
Strikingly, the level of IkappaBalpha mRNA in the nfkb-/- cells was only two-fold lower than in wild type, with even smaller differences in IkappaBbeta and IkappaBepsilon mRNA levels (Supplementary Figure S2B), suggesting that differential protein stability may account for different IkappaB protein levels in wild-type and nfkb-/- cells. Indeed, treating nfkb-/- cells with CHX resulted in rapid decreases of IkappaBalpha protein, whereas it remains stable in the wild-type cells beyond 2 h (Figure 2C). These results suggest that NF-kappaB has a regulatory role not only in controlling IkappaBalpha transcription, but also in stabilizing IkappaB proteins.
###end p 23
###begin p 24
We next investigated whether the dramatically different half-life of free and bound IkappaB proteins may be due to different mechanisms governing their degradation.
###end p 24
###begin p 25
###xml 444 453 432 441 <xref ref-type="fig" rid="f2">Figure 2D</xref>
###xml 570 579 547 556 <xref ref-type="fig" rid="f2">Figure 2E</xref>
IKK phosphorylation is a key mediator of the stimulus-induced degradation of NF-kappaB-bound IkappaB proteins, yet it is unclear if and how IKK may participate in the basal degradation of bound IkappaB. We first performed a kinase assay to examine the IKK activity of immunoprecipitated IKK complex from wild-type MEFs. Surprisingly, even in resting cells, a substantial amount of basal activity associated with the IKK complex was detectable (Figure 2D). In cells lacking the IKK catalytic subunits, IKKalpha and IKKbeta, no activation of NF-kappaB upon CHX treatment (Figure 2E) was observed, indicating that IKK-dependent phosphorylation is required for the basal turnover of NF-kappaB-bound IkappaB proteins.
###end p 25
###begin p 26
###xml 195 199 191 195 <italic>nfkb</italic>
###xml 199 202 195 198 <italic>&#8722;/&#8722;</italic>
###xml 199 202 195 198 <sup><italic>&#8722;/&#8722;</italic></sup>
###xml 214 238 210 234 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure S3A</xref>
###xml 378 382 358 362 <italic>nfkb</italic>
###xml 382 385 362 365 <italic>&#8722;/&#8722;</italic>
###xml 382 385 362 365 <sup><italic>&#8722;/&#8722;</italic></sup>
###xml 393 402 373 382 <xref ref-type="fig" rid="f2">Figure 2F</xref>
###xml 407 431 387 411 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure S3B</xref>
###xml 715 719 675 679 <italic>nfkb</italic>
###xml 719 722 679 682 <italic>&#8722;/&#8722;</italic>
###xml 719 722 679 682 <sup><italic>&#8722;/&#8722;</italic></sup>
###xml 730 739 690 699 <xref ref-type="fig" rid="f2">Figure 2G</xref>
###xml 913 917 861 865 <italic>nfkb</italic>
###xml 917 920 865 868 <italic>&#8722;/&#8722;</italic>
###xml 917 920 865 868 <sup><italic>&#8722;/&#8722;</italic></sup>
###xml 994 1003 942 951 <xref ref-type="fig" rid="f2">Figure 2H</xref>
We sought to determine if IKK activity is involved in the turnover of free IkappaB proteins as well. IP-IKK kinase assays determined that the basal and inducible IKK activities are intact in the nfkb-/- cell line (Supplementary Figure S3A). Treatment of wild-type cells with TNF led to the rapid degradation of IkappaBalpha, but did not affect the levels of IkappaBalpha in the nfkb-/- cells (Figure 2F and Supplementary Figure S3B), suggesting that the inducible IKK activity is not involved in the degradation of free IkappaBalpha. Further, the IKK inhibitor, sc-514, which diminishes the TNF-induced degradation of IkappaBalpha in wild-type cells, did not have an effect on the basal turnover of free IkappaB in nfkb-/- cells (Figure 2G). In contrast, the proteasome inhibitor MG132 prevented not only TNF-induced degradation of IkappaBalpha in wild-type cells, but also led to accumulation of free IkappaB in nfkb-/- cells, and prevented its degradation when cells were cotreated with CHX (Figure 2H).
###end p 26
###begin p 27
###xml 291 301 279 289 <xref ref-type="fig" rid="f2">Figures 2H</xref>
###xml 306 329 294 317 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure S2</xref>
###xml 526 535 506 515 <xref ref-type="fig" rid="f2">Figure 2E</xref>
###xml 640 661 612 633 <xref ref-type="bibr" rid="b15">Pando and Verma, 2000</xref>
###xml 686 693 658 665 <xref ref-type="table" rid="t1">Table I</xref>
Based on our new biochemical data, we revised the parameter values governing degradation of IkappaB proteins within the NF-kappaB signaling module and incorporated these into our mathematical model (now termed model 1.1). Half-lives for free IkappaB proteins were determined to be 5-10 min (Figures 2H and Supplementary Figure S2, allowing us to calculate the respective first order rate constants (deg1-3). Our data highly constrained IKK-independent degradation rate constants (deg4-6) for NF-kappaB-bound IkappaB proteins (Figure 2E). While previous studies suggested that NF-kappaB stabilized free IkappaB degradation by a factor of 5 (Pando and Verma, 2000), our new measurements (Table I) indicate an NF-kappaB effect of 2000-fold with respect to the IKK-independent degradation of IkappaB proteins. This large discrepancy likely lies in the facts that (i) we have used a clean genetic system to isolate free endogenous IkappaB from NF-kappaB proteins, and have thus obtained a much faster degradation rate for free IkappaB and (ii) we have determined that degradation of NF-kappaB-bound IkappaB proteins can only occur through an IKK-involving mechanism and have thus drastically decreased the IKK-independent degradation rate of bound IkappaB.
###end p 27
###begin p 28
###xml 49 56 49 56 <xref ref-type="table" rid="t1">Table I</xref>
###xml 119 124 119 124 <italic>et al</italic>
###xml 110 130 110 130 <xref ref-type="bibr" rid="b6">Hoffmann <italic>et al</italic>, 2002</xref>
###xml 244 266 236 258 <xref ref-type="supplementary-material" rid="S1">Supplementary Table SI</xref>
###xml 373 378 357 362 <italic>et al</italic>
###xml 367 384 351 368 <xref ref-type="bibr" rid="b21">Zandi <italic>et al</italic>, 1998</xref>
###xml 492 514 472 494 <xref ref-type="supplementary-material" rid="S1">Supplementary Table SI</xref>
###xml 520 545 500 525 <xref ref-type="supplementary-material" rid="S1">Supplementary information</xref>
###xml 650 655 630 635 <italic>et al</italic>
###xml 644 661 624 641 <xref ref-type="bibr" rid="b21">Zandi <italic>et al</italic>, 1998</xref>
After incorporation of the new rate constants in Table I, we performed model fitting as described previously (Hoffmann et al, 2002) to obtain new degradation rate constants for IKK-induced degradation of NF-kappaB-bound IkappaB proteins (r4-6; Supplementary Table SI). As IKK-mediated phosphorylation of IkappaB is five-fold more efficient when NF-kappaB is present (Zandi et al, 1998), we divided the newly determined r4-6 by 5 to determine IKK-induced degradation of free IkappaB proteins (Supplementary Table SI, see Supplementary information for rate constant derivations). Including eight-fold differential IKK association rate constants (Zandi et al, 1998), the combined NF-kappaB effect on IKK-mediated degradation of free and bound IkappaB proteins is almost 50-fold.
###end p 28
###begin p 29
Our results emphasize that NF-kappaB determines the degradation mechanism of IkappaB proteins. When bound to NF-kappaB, IkappaB turnover is slow and dependent on the basal activity of IKK. In contrast, when not bound to NF-kappaB, IkappaB degradation is rapid and independent of IKK activity.
###end p 29
###begin title 30
Cross-regulation between IkappaB proteins via half-life control by NF-kappaB
###end title 30
###begin p 31
###xml 154 159 150 155 <italic>et al</italic>
###xml 145 165 141 161 <xref ref-type="bibr" rid="b6">Hoffmann <italic>et al</italic>, 2002</xref>
###xml 244 252 240 248 <xref ref-type="table" rid="t1">Tables I</xref>
###xml 257 278 253 274 <xref ref-type="supplementary-material" rid="S1">Supplementary Table I</xref>
###xml 292 301 288 297 <xref ref-type="fig" rid="f3">Figure 3A</xref>
###xml 620 640 608 628 <xref ref-type="bibr" rid="b16">Rice and Ernst, 1993</xref>
###xml 715 720 703 708 <italic>et al</italic>
###xml 705 726 693 714 <xref ref-type="bibr" rid="b13">Lipniacki <italic>et al</italic>, 2004</xref>
###xml 620 624 <span type="species:ncbi:4530">Rice</span>
We compared the steady-state levels of IkappaB predicted for unstimulated cells by the previous version of the model (referred to as model 1.0) (Hoffmann et al, 2002) and the new version of the model that incorporates the new rate constants of Tables I and Supplementary Table I (model 1.1) (Figure 3A, white and gray bars, respectively). The new degradation rate constants result in predictions of a much smaller pool of free IkappaB protein, as well as less total cellular IkappaB protein. The simulation results produced with the new model (1.1) are therefore in much better agreement with experimental observations (Rice and Ernst, 1993) than those with the previous model. Although a previous study (Lipniacki et al, 2004) lowered the IkappaB synthesis rate to correct the model-predicted ratio of free to bound IkappaB protein in the steady state, our new data indicate that the rapid free IkappaB degradation necessitates a high synthesis rate.
###end p 31
###begin p 32
###xml 285 294 265 274 <xref ref-type="fig" rid="f3">Figure 3B</xref>
###xml 354 363 334 343 <xref ref-type="fig" rid="f3">Figure 3C</xref>
###xml 794 803 746 755 <xref ref-type="fig" rid="f3">Figure 3B</xref>
###xml 849 858 801 810 <xref ref-type="fig" rid="f3">Figure 3C</xref>
Next, we examined the consequences of the new degradation parameters on constitutive NF-kappaB activity in a series of IkappaB knockout cell lines. The previous model predicts that the removal of IkappaBalpha results in high levels of nuclear NF-kappaB activity in unstimulated cells (Figure 3B), which does not match with our experimental observations (Figure 3C). The differential degradation rates of bound and unbound IkappaB protein may result in molecular compensation among the IkappaB isoforms; upon deletion of a single IkappaB isoform, the newly available NF-kappaB may act to stabilize the remaining IkappaB isoforms, resulting in the cytoplasmic retention of NF-kappaB. Indeed, model 1.1 predicts a lower level of NF-kappaB activity in unstimulated knockout cells than version 1.0 (Figure 3B, compare white and gray bars). EMSA results (Figure 3C) confirm the new predictions, indicating that functional IkappaB compensation via differential half-life control indeed exists.
###end p 32
###begin p 33
###xml 15 22 15 18 <italic>i&#954;b</italic>
###xml 27 30 19 22 <sup>&#8722;/&#8722;</sup>
###xml 34 37 23 26 <sup>&#8722;/&#8722;</sup>
###xml 296 301 257 262 <italic>et al</italic>
###xml 289 307 250 268 <xref ref-type="bibr" rid="b11">Kearns <italic>et al</italic>, 2006</xref>
###xml 445 454 402 411 <xref ref-type="fig" rid="f3">Figure 3B</xref>
###xml 613 614 560 561 <italic>i</italic>
###xml 619 620 562 563 <italic>b</italic>
###xml 625 628 564 567 <italic>&#8722;/&#8722;</italic>
###xml 625 628 564 567 <sup><italic>&#8722;/&#8722;</italic></sup>
###xml 658 667 597 606 <xref ref-type="fig" rid="f3">Figure 3D</xref>
###xml 721 730 650 659 <xref ref-type="fig" rid="f3">Figure 3E</xref>
###xml 920 921 837 838 <italic>i</italic>
###xml 926 927 839 840 <italic>b</italic>
###xml 932 935 841 844 <sup>&#8722;/&#8722;</sup>
In the case of ikappabalpha-/-beta-/- cells where IkappaBepsilon is the only isoform present, our model predicts a markedly higher level of NF-kappaB activity than seen experimentally. However, we have recently characterized an NF-kappaB-inducible IkappaBepsilon mRNA synthesis mechanism (Kearns et al, 2006). Incorporation of this feedback mechanism into the model (referred to as model 1.2) indeed lowers the predicted basal NF-kappaB levels (Figure 3B, black bars) to levels that are in good agreement with the EMSA results. We measured IkappaBepsilon mRNA levels and found that they are indeed upregulated in ikappabalpha-/- cells compared to wild type (Figure 3D), resulting in higher IkappaBepsilon protein levels (Figure 3E). To determine whether this effect was the result of homeostatic regulation within the NF-kappaB signaling module, we used a retroviral transgene to reconstitute IkappaBalpha expression in ikappabalpha-/- cells. Indeed, we found that IkappaBepsilon upregulation was reversible, confirming that even in resting cells constitutive NF-kappaB activity plays a role in transcriptional regulation of its inhibitors to controls its own steady-state activity.
###end p 33
###begin title 34
Homeostatic control via distinct IkappaB degradation pathways
###end title 34
###begin p 35
Our analysis of the NF-kappaB signaling module in unstimulated cells reveals a highly dynamic homeostatic state that is controlled by multiple synthesis and degradation mechanisms of the regulatory IkappaB proteins. As such we find that NF-kappaB itself has two roles in regulating its own basal activity. NF-kappaB binding to IkappaB proteins removes them from this rapid degradation pathway, and sensitizes them to a slow degradation mechanism that is dependent on basal IKK activity. Second, constitutive NF-kappaB activity also impacts transcription rates of IkappaBalpha and IkappaBepsilon, thus providing for negative feedback even in the absence of an external stimulus.
###end p 35
###begin p 36
Our studies identify the free IkappaB protein degradation pathway as a major determinant of constitutive NF-kappaB and of stimulus responsiveness of the NF-kappaB signaling module. Given this hitherto unappreciated importance, determining the enzymatic and potentially regulatory mechanisms of the free IkappaB degradation pathway is critical for understanding the regulation of NF-kappaB in diverse physiological and pathological settings.
###end p 36
###begin p 37
###xml 557 562 534 539 <italic>et al</italic>
###xml 552 568 529 545 <xref ref-type="bibr" rid="b7">Ivan <italic>et al</italic>, 2001</xref>
###xml 579 584 556 561 <italic>et al</italic>
###xml 570 590 547 567 <xref ref-type="bibr" rid="b8">Jaakkola <italic>et al</italic>, 2001</xref>
###xml 592 602 569 579 <xref ref-type="bibr" rid="b14">Moon, 2005</xref>
Owing to the dynamic nature of the IkappaB-NF-kappaB equilibrium, the majority of newly synthesized IkappaB is likely degraded before ever binding NF-kappaB. However, this is not unlike other signal transduction pathways that consume significant cellular resources for the maintenance of a dynamic homeostatic state. For example, the transcription factors p53, HIF-1alpha, and beta-catenin are continually synthesized and degraded. Upon signaling, the respective degradation pathways are inhibited to allow for their nuclear accumulation and function (Ivan et al, 2001; Jaakkola et al, 2001; Moon, 2005). How may this energy-consuming process of maintaining a dynamic homeostasis benefit the cell? Future computational studies may suggest that homeostatic control of the NF-kappaB signaling module confers sensitivity to signals but ensures a very steady low equilibrium activity that is less likely to drift (D Barken, unpublished results). In addition, combined computational and experimental studies may demonstrate that such a dynamic equilibrium state sensitizes the signaling pathway to metabolic changes, such that stress conditions constitute an input signal that results in cellular responses (Ellen L O'Dea, unpublished results).
###end p 37
###begin title 38
Materials and methods
###end title 38
###begin title 39
Cells and reagents
###end title 39
###begin p 40
###xml 121 126 121 126 <italic>et al</italic>
###xml 112 132 112 132 <xref ref-type="bibr" rid="b6">Hoffmann <italic>et al</italic>, 2002</xref>
###xml 135 139 135 139 <italic>rela</italic>
###xml 139 142 139 142 <italic>&#8722;/&#8722;</italic>
###xml 139 142 139 142 <sup><italic>&#8722;/&#8722;</italic></sup>
###xml 142 146 142 146 <italic>crel</italic>
###xml 146 149 146 149 <italic>&#8722;/&#8722;</italic>
###xml 146 149 146 149 <sup><italic>&#8722;/&#8722;</italic></sup>
###xml 149 154 149 154 <italic>nfkb1</italic>
###xml 154 157 154 157 <italic>&#8722;/&#8722;</italic>
###xml 154 157 154 157 <sup><italic>&#8722;/&#8722;</italic></sup>
###xml 206 210 206 210 <italic>rela</italic>
###xml 210 213 210 213 <italic>+/&#8722;</italic>
###xml 210 213 210 213 <sup><italic>+/&#8722;</italic></sup>
###xml 213 217 213 217 <italic>crel</italic>
###xml 217 220 217 220 <italic>&#8722;/&#8722;</italic>
###xml 217 220 217 220 <sup><italic>&#8722;/&#8722;</italic></sup>
###xml 220 225 220 225 <italic>nfkb1</italic>
###xml 225 228 225 228 <italic>&#8722;/&#8722;</italic>
###xml 225 228 225 228 <sup><italic>&#8722;/&#8722;</italic></sup>
###xml 238 239 238 239 <italic>i</italic>
###xml 244 245 240 241 <italic>b</italic>
###xml 250 253 242 245 <sup>&#8722;/&#8722;</sup>
###xml 257 260 246 249 <sup>&#8722;/&#8722;</sup>
###xml 267 270 250 253 <sup>&#8722;/&#8722;</sup>
###xml 306 310 289 293 <italic>ikk1</italic>
###xml 310 313 293 296 <italic>&#8722;/&#8722;</italic>
###xml 310 313 293 296 <sup><italic>&#8722;/&#8722;</italic></sup>
###xml 313 317 296 300 <italic>ikk2</italic>
###xml 317 320 300 303 <italic>&#8722;/&#8722;</italic>
###xml 317 320 300 303 <sup><italic>&#8722;/&#8722;</italic></sup>
###xml 362 363 345 346 <italic>i</italic>
###xml 368 369 347 348 <italic>b</italic>
###xml 374 377 349 352 <sup>&#8722;/&#8722;</sup>
###xml 739 741 681 683 <sup>35</sup>
###xml 229 233 <span type="species:ncbi:10090">mice</span>
###xml 503 509 <span type="species:ncbi:10090">murine</span>
Primary and 3T3 immortalized MEF were generated from E12.5-14.5 embryos and maintained as described previously (Hoffmann et al, 2002). rela-/-crel-/-nfkb1-/- MEFs were generated from E12.5-timed matings of rela+/-crel-/-nfkb1-/- mice and ikappabalpha-/-beta-/-epsilon-/- cells will be described elsewhere. ikk1-/-ikk2-/- cells were a kind gift from Inder Verma. ikappabalpha-/- MEF lines reconstituted with pBabe-IkappaBalpha and empty vector control were a generous gift from Erika Mathes. Recombinant murine TNF was from Roche; CHX, sc-514, and MG132 from Sigma. RelA/p65 (sc-372), RelB (sc-226), cRel (sc-71), IkappaBalpha (sc-371), IkappaBbeta (sc-946), and IkappaBepsilon (sc-7156) antibodies were from Santa Cruz Biotechnology. Trans35S-methionine label was from MP Biomedicals.
###end p 40
###begin title 41
Biochemical analysis
###end title 41
###begin p 42
###xml 242 247 242 247 <italic>et al</italic>
###xml 233 253 233 253 <xref ref-type="bibr" rid="b6">Hoffmann <italic>et al</italic>, 2002</xref>
###xml 312 317 312 317 <italic>et al</italic>
###xml 305 324 305 324 <xref ref-type="bibr" rid="b19">Werner <italic>et al</italic> (2005)</xref>
###xml 670 675 670 675 <italic>et al</italic>
###xml 663 682 663 682 <xref ref-type="bibr" rid="b11">Kearns <italic>et al</italic> (2006)</xref>
Whole-cell extracts were prepared in RIPA buffer and equivalent protein amounts subjected to immunoblot analysis using ECL-plus (Amersham/GE Healthcare). Nuclear extracts were prepared and used for electrophoretic EMSA as described (Hoffmann et al, 2002). Immunoprecipitation kinase assay performed as in Werner et al (2005). Signals were quantified using a phosphorimager (Molecular Dynamics) and ImageQuant software version 5.2 (GE Healthcare). Dilution series with knockout extracts assured that Western blot signals were in the linear range. Total cellular RNA was isolated with Trizol reagent (Invitrogen) and used for RNase protection assay as described in Kearns et al (2006).
###end p 42
###begin p 43
###xml 36 38 35 37 <sup>35</sup>
###xml 154 156 153 155 <sup>35</sup>
Cells were labeled with 200 muCi/ml 35S-methionine label for indicated times. Whole-cell extracts were prepared in RIPA buffer and dried on filter paper. 35S-Met incorporation was measured by scintillation count and CHX-treated cells versus untreated cells were compared to measure the percentage of translational inhibition.
###end p 43
###begin title 44
Computational modeling
###end title 44
###begin p 45
###xml 95 100 87 92 <italic>et al</italic>
###xml 86 107 78 99 <xref ref-type="bibr" rid="b6">Hoffmann <italic>et al</italic> (2002)</xref>
###xml 155 164 147 156 <xref ref-type="fig" rid="f1">Figure 1.</xref>
###xml 222 229 214 221 <xref ref-type="table" rid="t1">Table I</xref>
###xml 346 351 338 343 <italic>et al</italic>
###xml 337 357 329 349 <xref ref-type="bibr" rid="b6">Hoffmann <italic>et al</italic>, 2002</xref>
###xml 454 479 446 471 <xref ref-type="supplementary-material" rid="S1">Supplementary information</xref>
The mathematical model of the IKK-IkappaB-NF-kappaB signaling module was described in Hoffmann et al (2002). This model (version 1.0) was used to generate Figure 1. Model version 1.1 includes the parameter values shown in Table I and baseline level of IKK of 1 nM. Simulations were performed in Matlab and Excel as described previously (Hoffmann et al, 2002) with extended equilibration times. A complete list of the parameter values can be found in the Supplementary information. Graphs were generated in Excel. The Matlab code file is available upon request, and the SBML code is available at the MSB website.
###end p 45
###begin title 46
Supplementary Material
###end title 46
###begin p 47
Supplementary Data
###end p 47
###begin p 48
Structured Data
###end p 48
###begin p 49
We thank Erika Mathes, Gouri Ghosh, and Betsy Komives for insightful discussions, and Gouri Ghosh for critical reading of the manuscript. We are grateful to Santa Cruz Biotechnology for antibodies. EO is supported by the Heme Training Grant, JDK by the Molecular Biophysics Training Grant, DB by the UCSD Bioinformatics Graduate Training Grant, and SLW by an NSF Graduate Fellowship. This study was supported by NIH grants GM72024, GM69013, and GM071573.
###end p 49
###begin article-title 50
Mechanism of direct degradation of IkappaBalpha by 20S proteasome.
###end article-title 50
###begin article-title 51
PKC-zeta-associated CK2 participates in the turnover of free IkappaBalpha.
###end article-title 51
###begin article-title 52
Signal transduction and the control of gene expression.
###end article-title 52
###begin article-title 53
NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses.
###end article-title 53
###begin article-title 54
Circuitry of nuclear factor kappaB signaling.
###end article-title 54
###begin article-title 55
The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation.
###end article-title 55
###begin article-title 56
###xml 91 92 91 92 <sub>2</sub>
HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing.
###end article-title 56
###begin article-title 57
###xml 75 76 75 76 <sub>2</sub>
Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.
###end article-title 57
###begin article-title 58
Nuclear factor-kappaB in cancer development and progression.
###end article-title 58
###begin article-title 59
CK2 is a C-terminal IkappaB kinase responsible for NF-kappaB activation during the UV response.
###end article-title 59
###begin article-title 60
IkappaBepsilon provides negative feedback to control NF-kappaB oscillations, signaling dynamics, and inflammatory gene expression.
###end article-title 60
###begin article-title 61
###xml 116 123 116 123 <italic>in vivo</italic>
Different mechanisms control signal-induced degradation and basal turnover of the NF-kappaB inhibitor IkappaB alpha in vivo.
###end article-title 61
###begin article-title 62
Mathematical model of NF-kappaB regulatory module.
###end article-title 62
###begin article-title 63
Wnt/beta-catenin pathway.
###end article-title 63
###begin article-title 64
Signal-dependent and -independent degradation of free and NF-kappa B-bound IkappaBalpha.
###end article-title 64
###begin article-title 65
###xml 0 7 0 7 <italic>In vivo</italic>
In vivo control of NF-kappa B activation by I kappa B alpha.
###end article-title 65
###begin article-title 66
Constitutive phosphorylation of IkappaBalpha by casein kinase II occurs preferentially at serine 293: requirement for degradation of free IkappaBalpha.
###end article-title 66
###begin article-title 67
The p65 subunit of NF-kappa B regulates I kappa B by two distinct mechanisms.
###end article-title 67
###begin article-title 68
Stimulus specificity of gene expression programs determined by temporal control of IKK activity.
###end article-title 68
###begin article-title 69
Identification of the receptor component of the IkappaBalpha-ubiquitin ligase.
###end article-title 69
###begin article-title 70
Direct phosphorylation of IkappaB by IKKalpha and IKKbeta: discrimination between free and NF-kappaB-bound substrate.
###end article-title 70
###begin p 71
###xml 118 119 114 115 <bold>A</bold>
###xml 279 280 271 272 <bold>B</bold>
###xml 558 559 526 527 <bold>C</bold>
###xml 854 855 818 819 <bold>D</bold>
###xml 856 857 820 821 <bold>G</bold>
###xml 905 906 865 866 <italic>y</italic>
###xml 1026 1027 986 987 <italic>x</italic>
Exploring the relative importance of IkappaB degradation mechanisms by computational parameter sensitivity analysis. (A) Schematic of the NF-kappaB signaling module and its physiological importance in the transduction of diverse inflammatory, developmental, and stress signals. (B) Illustration of the four IkappaB degradation pathways within the NF-kappaB signaling module. deg1 and deg4 are IKK-independent degradation rate constants for free and bound IkappaBalpha. r1 and r4 are IKK-dependent degradation rate constants for free and bound IkappaBalpha. (C) Computational simulation of NF-kappaB activation over a 6-h time course. TNF stimulation begins at time 0, and is removed at 4 h. Mean activity in the first hour of stimulation and the second hour after removal of the stimulus (shaded in gray) were used to create the plots in (D-F) and (G). (D-G) Graphs showing the average nuclear NF-kappaB (y axis) during the first hour (D, F) or during the second hour after 4 h (E, G) of TNF stimulation for different values (x axis) of the IKK-dependent (D, E) or -independent (F, G) degradation rate constants of free (blue line) and bound (red line) IkappaB.
###end p 71
###begin p 72
###xml 93 94 85 86 <bold>A</bold>
###xml 240 241 227 228 <bold>B</bold>
###xml 307 310 290 293 <italic>ikb</italic>
###xml 314 317 294 297 <italic>&#8722;/&#8722;</italic>
###xml 314 317 294 297 <sup><italic>&#8722;/&#8722;</italic></sup>
###xml 324 327 298 301 <italic>&#8722;/&#8722;</italic>
###xml 324 327 298 301 <sup><italic>&#8722;/&#8722;</italic></sup>
###xml 329 332 303 306 <italic>ikb</italic>
###xml 337 340 307 310 <italic>&#8722;/&#8722;</italic>
###xml 337 340 307 310 <sup><italic>&#8722;/&#8722;</italic></sup>
###xml 347 350 311 314 <italic>&#8722;/&#8722;</italic>
###xml 347 350 311 314 <sup><italic>&#8722;/&#8722;</italic></sup>
###xml 355 358 319 322 <italic>ikb</italic>
###xml 363 366 323 326 <italic>&#8722;/&#8722;</italic>
###xml 363 366 323 326 <sup><italic>&#8722;/&#8722;</italic></sup>
###xml 371 373 328 330 <italic>/&#8722;</italic>
###xml 370 373 327 330 <sup>&#8722;<italic>/&#8722;</italic></sup>
###xml 424 425 380 381 <bold>C</bold>
###xml 486 490 434 438 <italic>nfkb</italic>
###xml 490 493 438 441 <italic>&#8722;/&#8722;</italic>
###xml 490 493 438 441 <sup><italic>&#8722;/&#8722;</italic></sup>
###xml 526 527 474 475 <italic>i</italic>
###xml 532 533 476 477 <italic>b</italic>
###xml 538 541 478 481 <italic>&#8722;/&#8722;</italic>
###xml 538 541 478 481 <sup><italic>&#8722;/&#8722;</italic></sup>
###xml 545 548 482 485 <italic>&#8722;/&#8722;</italic>
###xml 545 548 482 485 <sup><italic>&#8722;/&#8722;</italic></sup>
###xml 555 558 486 489 <italic>&#8722;/&#8722;</italic>
###xml 555 558 486 489 <sup><italic>&#8722;/&#8722;</italic></sup>
###xml 571 572 502 503 <italic>i</italic>
###xml 577 578 504 505 <italic>b</italic>
###xml 583 586 506 509 <italic>&#8722;/&#8722;</italic>
###xml 583 586 506 509 <sup><italic>&#8722;/&#8722;</italic></sup>
###xml 590 593 510 513 <italic>&#8722;/&#8722;</italic>
###xml 590 593 510 513 <sup><italic>&#8722;/&#8722;</italic></sup>
###xml 600 603 514 517 <italic>&#8722;/&#8722;</italic>
###xml 600 603 514 517 <sup><italic>&#8722;/&#8722;</italic></sup>
###xml 693 697 599 603 <italic>nfkb</italic>
###xml 697 700 603 606 <italic>&#8722;/&#8722;</italic>
###xml 697 700 603 606 <sup><italic>&#8722;/&#8722;</italic></sup>
###xml 771 772 677 678 <bold>D</bold>
###xml 879 887 781 789 <italic>in vitro</italic>
###xml 960 961 862 863 <bold>E</bold>
###xml 1027 1030 925 928 <italic>ikk</italic>
###xml 1035 1038 929 932 <italic>&#8722;/&#8722;</italic>
###xml 1035 1038 929 932 <sup><italic>&#8722;/&#8722;</italic></sup>
###xml 1042 1045 933 936 <italic>&#8722;/&#8722;</italic>
###xml 1042 1045 933 936 <sup><italic>&#8722;/&#8722;</italic></sup>
###xml 1093 1094 983 984 <bold>F</bold>
###xml 1186 1190 1068 1072 <italic>rela</italic>
###xml 1190 1193 1072 1075 <italic>&#8722;/&#8722;</italic>
###xml 1190 1193 1072 1075 <sup><italic>&#8722;/&#8722;</italic></sup>
###xml 1193 1197 1075 1079 <italic>crel</italic>
###xml 1197 1200 1079 1082 <italic>&#8722;/&#8722;</italic>
###xml 1197 1200 1079 1082 <sup><italic>&#8722;/&#8722;</italic></sup>
###xml 1200 1205 1082 1087 <italic>nfkb1</italic>
###xml 1205 1208 1087 1090 <italic>&#8722;/&#8722;</italic>
###xml 1205 1208 1087 1090 <sup><italic>&#8722;/&#8722;</italic></sup>
###xml 1217 1218 1099 1100 <bold>G</bold>
###xml 1516 1517 1381 1382 <bold>H</bold>
###xml 1755 1759 1600 1604 <italic>nfkb</italic>
###xml 1759 1762 1604 1607 <italic>&#8722;/&#8722;</italic>
###xml 1759 1762 1604 1607 <sup><italic>&#8722;/&#8722;</italic></sup>
Experimental studies of degradation pathways of NF-kappaB-bound and -free IkappaB proteins. (A) NF-kappaB activity as measured by EMSA of nuclear extracts from wild-type cells treated with 10 mug/ml CHX or 1 ng/ml TNF for indicated times. (B) NF-kappaB activity as measured by EMSA of nuclear extracts from ikbbeta-/-epsilon-/-, ikbalpha-/-epsilon-/-, or ikbalpha-/-beta-/- cells treated with 10 mug/ml CHX or 1 ng/ml TNF. (C) Western blot for IkappaBalpha in CHX-treated wild-type and nfkb-/- cells. The first two lanes show ikappabalpha-/-beta-/-epsilon-/- extract and ikappabalpha-/-beta-/-epsilon-/- extract mixed with 5% wild-type extract to show the protein level of IkappaBalpha in the nfkb-/- cells was approximately 5% that in the wild-type cells at time zero. (D) Cytoplasmic extracts of wild-type cells were immunoprecipitated with IKKgamma antibody and subject to an in vitro kinase assay. In the 'mock' lane, no antibody was added during the IP. (E) NF-kappaB activity as measured by EMSA of nuclear extracts from ikkalpha-/-beta-/- or wild-type MEFs treated with 10 mug/ml CHX. (F) Western blot for IkappaBalpha of protein extracts from TNF (1 ng/ml)-treated wild-type or rela-/-crel-/-nfkb1-/- cells. (G) Western blots for IkappaBalpha of protein extracts from TNF-treated wild-type cells (top panel) in the presence or absence of the IKK-inhibitor sc-514. Bottom panels show Western blots for IkappaBalpha of protein extracts from CHX (10 mug/ml)-treated cells in the presence or absence of sc-514. (H) Western blots for IkappaBalpha of protein extracts from wild-type cells treated with TNFalpha (1 ng/ml) with or without the presence of the proteasome inhibitor MG132 (top panel). Western blots for IkappaBalpha of protein extracts from nfkb-/- cells treated with 10 mug/ml CHX, 10 muM MG132, or both.
###end p 72
###begin p 73
###xml 66 67 62 63 <bold>A</bold>
###xml 302 303 265 266 <bold>B</bold>
###xml 381 384 340 343 <italic>ikb</italic>
###xml 384 387 343 346 <italic>&#8722;/&#8722;</italic>
###xml 384 387 343 346 <sup><italic>&#8722;/&#8722;</italic></sup>
###xml 495 496 454 455 <bold>C</bold>
###xml 585 586 540 541 <italic>i</italic>
###xml 591 592 542 543 <italic>b</italic>
###xml 592 595 543 546 <italic>&#8722;/&#8722;</italic>
###xml 592 595 543 546 <sup><italic>&#8722;/&#8722;</italic></sup>
###xml 767 768 714 715 <bold>D</bold>
###xml 861 862 798 799 <italic>i</italic>
###xml 867 868 800 801 <italic>b</italic>
###xml 873 876 802 805 <italic>&#8722;/&#8722;</italic>
###xml 873 876 802 805 <sup><italic>&#8722;/&#8722;</italic></sup>
###xml 913 914 842 843 <italic>i</italic>
###xml 919 920 844 845 <italic>b</italic>
###xml 925 928 846 849 <italic>&#8722;/&#8722;</italic>
###xml 925 928 846 849 <sup><italic>&#8722;/&#8722;</italic></sup>
###xml 959 960 880 881 <italic>i</italic>
###xml 965 966 882 883 <italic>b</italic>
###xml 1020 1021 933 934 <bold>E</bold>
An improved model of the homeostatic NF-kappaB signaling module. (A) Model calculations of IkappaBalpha, beta, and epsilon protein levels (nM) in unstimulated cells for total IkappaB, free IkappaB, or NF-kappaB-bound IkappaB. Model 1.0 predictions are white bars, model 1.1 predictions are gray bars. (B) Model calculations of NF-kappaB activity (nM) in unstimulated wild-type and ikb-/- cells predicted by model version 1.0 (white bars), version 1.1 (gray bars), and version 1.2 (black bars). (C) NF-kappaB activity in untreated cells as measured by EMSA of nuclear extracts from the ikappab-/- cell genotype labeled above each lane. The last three lanes are controls for the NF-kappaB band and are nuclear extracts from wild-type cells treated with TNF (1 ng/ml). (D) RNase protection assay showing levels of IkappaBepsilon mRNA in untreated wild-type cells, ikappabalpha-/- cells with empty vector control, or ikappabalpha-/- cells expressing a retroviral ikappabalpha transgene. GAPDH is used as a loading control. (E) Western blots for IkappaBepsilon and IkappaBalpha in resting cells. The cell genotype is listed above each lane.
###end p 73
###begin p 74
Rate constants for IKK-independent IkappaB degradation: a role for NF-kappaB
###end p 74
###begin p 75
New rate constants governing the uninduced IKK-independent degradation of IkappaB proteins derived from experiments in this paper and used in an updated version of the mathematical model. The ratio of IkappaB degradation rate constants in the presence and absence of NF-kappaB is defined as the 'NF-kappaB effect'.
###end p 75

